Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SION vs AARD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AARD Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 2–3 Matrix Metrics)

AARD Overall Winner 6-Pillar Tally: SION 2 – 2 AARD (2 Tie) Matrix Metrics: SION 3 – 2 AARD

As of Nov 16, 2026, Aardvark Therapeutics, Inc. (AARD) is the stronger overall head-to-head candidate over Sionna Therapeutics, Inc. (SION) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). SION carries a Unified Composite Score of 45.6/100 (HOLD) at $3.12 (N/M Forward P/E, 0.0% operating margin), whereas AARD carries 57.5/100 (HOLD) at $1.26 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: SION is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.9); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SION vs AARD
SION NASDAQ
Sionna Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.12
-6.31% 1D
Market Cap $150.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.97β · 78% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 34.0 Fund 50.0 Flow 67.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.6%), weak momentum, RSI 32
RSI-14: 31.9 · SMA20: $3.67 · SMA50: $4.84
AARD NASDAQ Head-to-Head Winner
Aardvark Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.26
-5.26% 1D
Market Cap $29.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.10β · 288% Vol
Unified Composite Score
57.5 / 100 HOLD
Tech 79.0 Fund 63.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.9%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $1.74 · SMA50: $3.68

6-Pillar Scorecard Institutional Category Breakdown (SION 2 – 2 AARD)

Columns: Metric · SION · AARD
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale SION
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $150.6M $29.1M
3. Profitability & Quality SION
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -39.0% -66.0%
4. Balance Sheet & Cash Flow AARD
Cash Generation (TTM) -$80M -$69M
Cash Flow Margin N/A N/A
Net Cash / Leverage $76M Net Cash $73M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AARD
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 87.7% (10th %ile) 147.3% (26th %ile)
Put/Call OI Skew 93.27x (Put-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SION (3) vs AARD (2)
Institutional Metric SION AARD Criterion Row Edge
Market Capitalization
Scale
$150.6M $29.1M Larger Scale SION
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-39.0% -66.0% Higher ROE SION
52-Week Range Position
Momentum
0% ($3–$55) 2% ($1–$17) Stronger Trend AARD
Beta / 30D Volatility
Risk Regime
1.97β · 78% Vol 4.10β · 288% Vol Lower Realized Risk SION
Unified Institutional Score
Composite Signal
45.6 / 100 (HOLD) 57.5 / 100 (HOLD) Higher Composite AARD
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($76M Net Cash) -$69M ($73M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SION +46.88 pp
SION: -19.79% · AARD: -66.67%
3M Horizon SION +32.03 pp
SION: -47.47% · AARD: -79.5%
6M Horizon AARD +20.95 pp
SION: -92.05% · AARD: -71.1%
1Y Horizon AARD +2.9 pp
SION: -91.3% · AARD: -88.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SION vs AARD. Trailing 12-month operating profitability (SION 0.0% vs AARD 0.0%) and valuation multiples (SION N/M vs AARD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SION ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-39.0% · N/M
AARD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-66.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SION BREAKDOWN
45d in phase · OBV ACCUMULATION
Current IV 87.7%
IV Percentile 10th %ile
Put/Call OI Skew 93.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SION Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AARD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 147.3%
IV Percentile 26th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AARD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SION Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $150.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AARD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $29.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SION vs AARD Key Questions & Quantitative Answers

As of Nov 16, 2026, Aardvark Therapeutics, Inc. (AARD) is the stronger overall head-to-head candidate over Sionna Therapeutics, Inc. (SION) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). SION carries a Unified Composite Score of 45.6/100 (HOLD) at $3.12 (N/M Forward P/E, 0.0% operating margin), whereas AARD carries 57.5/100 (HOLD) at $1.26 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SION is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.9); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SION leads the Growth & Scale pillar: SION posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AARD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SION generates N/A in USD-normalized revenue versus N/A for AARD. In operating R&D and SG&A reinvestment, SION deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AARD.

SION and AARD trade at balanced relative valuation multiples. SION trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AARD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SION (-39.0% ROE) versus AARD (-66.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SION carries 87.7% implied volatility (10th %ile, Compressed (<25th %ile)), a 93.27x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.97β · 78% Vol realized risk). By comparison, AARD carries 147.3% implied volatility (26th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.10β · 288% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.